Breast Cancer,HER2+ Margetuximab vs Trastuzumab in Pretreated ERBB2-Positive Advanced Breast Cancer Jun 08, 2023
Breast Cancer,HER2+ Examining the Potential of Margetuximab in the Treatment of HER2+ Metastatic Breast Cancer May 19, 2023
Breast Cancer,HER2+ Phase 3 PRECIOUS Study: Pertuzumab Retreatment Benefits for HER2+ Cancer Patients Mar 28, 2023
Breast Cancer,HER2+ Fam-Trastuzumab Gains FDA Approval for HER2-Low Breast Cancer Treatment Mar 14, 2023
Breast Cancer,HER2+ HER2DX Test Correlates with Trastuzumab/Pertuzumab Therapy in HER2+/HR+ Breast Cancer Mar 14, 2023
Breast Cancer,HER2+ Comparing Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Metastatic Breast Cancer Phase 3 Trial Feb 24, 2023
Breast Cancer,HER2+ Adjuvant T-DM1 vs. Trastuzumab in Residual HER2+ Breast Cancer: KATHERINE Phase 3 Results Feb 24, 2023